FDA CV Requirements Sideline Sanofi’s Lixisenatide
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi will withdraw its NDA for the GLP-1 agonist for diabetes to await the final results of an ongoing cardiovascular outcomes trial. The decision could delay a U.S. launch of lixisenatide by three years.
You may also be interested in...
On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes
With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.